The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Clinical aspects of Alzheimer's disease
Abstract
Alzheimer's disease is a progressive, irreversible, incurable, neurodegenerative illness and the most common of the dementing disorders. It starts usually after 60 years of age and may span 8 to 12 years. The continuous and slow decline caused by this disease, is characterized by cognitive deterioration, loss of functional independence, changes in behaviour, and expanding needs for care. In the last three decades, the proteins predominating neuritic plaques and neurofibrillary tangles have been detected and researched: amyloid-beta protein in the plaques and hyperphosphorylated tau in the tangles. Alzheimer's disease is now considered a long-term process with a slow progress and with a prolonged development of pathological changes that precedes symptoms by years. AD is becoming one of the most problematic and expensive illness for the civilization, also known as "silent threat".
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
2017 Alzheimer's disease facts and figures
(2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.02.001 · Cited by 1,311
Galton, C. J. (2000) · Brain · doi:10.1093/brain/123.3.484 · Cited by 613
Perry, R. J., Watson, P., & Hodges, J. R. (2000) · Neuropsychologia · doi:10.1016/s0028-3932(99)00079-2 · Cited by 494
Slooter, A. J. C., Cruts, M., Kalmijn, S., Hofman, A., Breteler, M. M. B., Van Broeckhoven, C., & van Duijn, C. M. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.964 · Cited by 399
Romeo S Revnic, C., Revnic, F., & Voinea, S. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.06.033 · Cited by 369
O'Bryant, S. E., Mielke, M. M., Rissman, R. A., Lista, S., Vanderstichele, H., Zetterberg, H., Lewczuk, P., Posner, H., Hall, J., Johnson, L., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.014 · Cited by 303
Protection against Alzheimer's disease with apoE ∈2
Talbot, C., Lendon, C., Craddock, N., Shears, S., Morris, J., & Goate, A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92557-7 · Cited by 225
The Experience of Caring for a Family Member With Alzheimer's Disease
Butcher, H. K., Holkup, P. A., & Buckwalter, K. C. (2001) · Western Journal of Nursing Research · doi:10.1177/01939450122044943 · Cited by 187
Cited by
β-Amyloid Clustering around ASC Fibrils Boosts Its Toxicity in Microglia
Friker, L. L., Scheiblich, H., Hochheiser, I. V., Brinkschulte, R., Riedel, D., Latz, E., Geyer, M., & Heneka, M. T. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.025 · Cited by 191
Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses
(2024) · aging and disease · doi:10.14336/ad.2023.0608 · Cited by 183
Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol
Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104822 · Cited by 135
Influential role of 7-Ketocholesterol in the progression of Alzheimer’s disease
Mahalakshmi, K., Parimalanandhini, D., Sangeetha, R., Livya Catherene, M., Beulaja, M., Thiagarajan, R., Arumugam, M., Janarthanan, S., & Manikandan, R. (2021) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2021.106582 · Cited by 32
Development of new Alzheimer’s disease drug candidates using donepezil as a key model
Eissa, K. I., Kamel, M. M., Mohamed, L. W., & Kassab, A. E. (2023) · Archiv der Pharmazie · doi:10.1002/ardp.202200398 · Cited by 20
Metadata
- Authors
- Zvěřová, M.
- Venue
- Clinical Biochemistry
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 72
- Pages
- 3-6
- ISSN
- 0009-9120 (ISSN-L)
- OpenAlex
- W2941551392
- Cited by
- 306
- References
- 17
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical aspects of Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.clinbiochem.2019.04.015
- The paper
- Zvěřová, M. (2019). Clinical aspects of Alzheimer's disease. Clinical Biochemistry. https://doi.org/10.1016/j.clinbiochem.2019.04.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.